{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T08:34:58Z","timestamp":1793781298032,"version":"4.6.1"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013170","name":"Ono Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013170","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008883","name":"Nagoya City University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008883","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100024217","name":"Osaka International Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100024217","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.eclinm.2025.103689","type":"journal-article","created":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T06:43:05Z","timestamp":1766817785000},"page":"103689","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Nivolumab with definitive chemoradiotherapy for oesophageal squamous cell carcinoma (NOBEL): a multicentre, single-arm, phase 2 feasibility trial"],"prefix":"10.1016","volume":"91","author":[{"given":"Motoo","family":"Nomura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuyuki","family":"Sakanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juko","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1776-4309","authenticated-orcid":false,"given":"Shinya","family":"Ohashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chikatoshi","family":"Katada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akinori","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Amanuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiko","family":"Minashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1733-5072","authenticated-orcid":false,"given":"Ken","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Kojima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kengo","family":"Nagashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ihhwa","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harue","family":"Tada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiyoshi","family":"Nakakura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manabu","family":"Muto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eclinm.2025.103689_bib1","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Siegel","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.eclinm.2025.103689_bib2","author":"Kimura"},{"key":"10.1016\/j.eclinm.2025.103689_bib3","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0140-6736(24)00745-1","article-title":"Doublet chemotherapy, triplet chemotherapy, or doublet chemotherapy combined with radiotherapy as neoadjuvant treatment for locally advanced oesophageal cancer (JCOG1109 NExT): a randomised, controlled, open-label, phase 3 trial","volume":"404","author":"Kato","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.eclinm.2025.103689_bib4","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA1","article-title":"Prospective randomized multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (ESOPEC trial)","volume":"42","author":"Hoeppner","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eclinm.2025.103689_bib5","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1200\/JCO.2002.20.5.1167","article-title":"INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy","volume":"20","author":"Minsky","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eclinm.2025.103689_bib6","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.ijrobp.2022.07.007","article-title":"A single-arm confirmatory study of definitive chemoradiation therapy including salvage treatment for clinical stage II\/III esophageal squamous cell carcinoma (JCOG0909 study)","volume":"114","author":"Takeuchi","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eclinm.2025.103689_bib7","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/cas.12622","article-title":"Randomized study of low-dose versus standard-dose chemoradiotherapy for unresectable esophageal squamous cell carcinoma (JCOG0303)","volume":"106","author":"Shinoda","year":"2015","journal-title":"Cancer Sci"},{"key":"10.1016\/j.eclinm.2025.103689_bib8","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(21)01234-4","article-title":"Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study","volume":"398","author":"Sun","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.eclinm.2025.103689_bib9","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa2111380","article-title":"Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma","volume":"386","author":"Doki","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eclinm.2025.103689_bib10","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1016\/S1470-2045(19)30626-6","article-title":"Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial","volume":"20","author":"Kato","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eclinm.2025.103689_bib11","doi-asserted-by":"crossref","first-page":"4138","DOI":"10.1200\/JCO.20.01888","article-title":"Randomized phase III KEYNOTE-181 study of pembrolizumab versus chemotherapy in advanced esophageal cancer","volume":"38","author":"Kojima","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eclinm.2025.103689_bib12","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1200\/JCO.21.01308","article-title":"Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"40","author":"Spigel","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eclinm.2025.103689_bib13","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S0140-6736(24)00317-9","article-title":"Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11\/GOG-3047\/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial","volume":"403","author":"Lorusso","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.eclinm.2025.103689_bib14","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0143804","article-title":"Discovery of a good responder subtype of esophageal squamous cell carcinoma with cytotoxic T-lymphocyte signatures activated by chemoradiotherapy","volume":"10","author":"Tanaka","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.eclinm.2025.103689_bib16","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.eclinm.2025.103689_bib17","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s10388-016-0556-2","article-title":"Japanese classification of esophageal cancer, 11th edition: part II and III","volume":"14","year":"2017","journal-title":"Esophagus"},{"key":"10.1016\/j.eclinm.2025.103689_bib18","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1093\/jjco\/hyi095","article-title":"Clinical impact of criteria for complete response (CR) of primary site to treatment of esophageal cancer","volume":"35","author":"Tahara","year":"2005","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.eclinm.2025.103689_bib19","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1001\/jamaoncol.2017.1598","article-title":"Effect of the addition of cetuximab to paclitaxel, cisplatin, and radiation therapy for patients with esophageal cancer: the NRG oncology RTOG 0436 phase 3 randomized clinical trial","volume":"3","author":"Suntharalingam","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.eclinm.2025.103689_bib20","doi-asserted-by":"crossref","first-page":"4014","DOI":"10.1038\/s41467-021-24288-1","article-title":"Induction chemotherapy followed by definitive chemoradiotherapy versus chemoradiotherapy alone in esophageal squamous cell carcinoma: a randomized phase II trial","volume":"12","author":"Liu","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.eclinm.2025.103689_bib21","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.ijrobp.2016.08.016","article-title":"Radiation dose escalation in esophageal cancer revisited: a contemporary analysis of the national Cancer Data Base, 2004 to 2012","volume":"96","author":"Brower","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eclinm.2025.103689_bib22","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.1200\/JCO.20.03697","article-title":"Randomized study on dose escalation in definitive chemoradiation for patients with locally advanced esophageal cancer (ARTDECO study)","volume":"39","author":"Hulshof","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eclinm.2025.103689_bib23","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.ijrobp.2022.11.006","article-title":"High-dose versus standard-dose intensity-modulated radiotherapy with concurrent paclitaxel plus carboplatin for patients with thoracic esophageal squamous cell carcinoma: a randomized, multicenter, open-label, phase 3 superiority trial","volume":"115","author":"You","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eclinm.2025.103689_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.109700","article-title":"High-dose versus standard-dose radiotherapy in concurrent chemoradiotherapy for inoperable esophageal cancer: a systematic review and meta-analysis","volume":"184","author":"Yao","year":"2023","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.eclinm.2025.103689_bib25","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/S1470-2045(23)00060-8","article-title":"Toripalimab combined with definitive chemoradiotherapy in locally advanced oesophageal squamous cell carcinoma (EC-CRT-001): a single-arm, phase 2 trial","volume":"24","author":"Zhu","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eclinm.2025.103689_bib26","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1093\/jrr\/rry055","article-title":"Comparison of elective nodal irradiation and involved-field irradiation in esophageal squamous cell carcinoma: a meta-analysis","volume":"59","author":"Cheng","year":"2018","journal-title":"J Radiat Res"},{"key":"10.1016\/j.eclinm.2025.103689_bib27","doi-asserted-by":"crossref","first-page":"7460","DOI":"10.1002\/cam4.3409","article-title":"Comparison between the effects of elective nodal irradiation and involved-field irradiation on long-term survival in thoracic esophageal squamous cell carcinoma patients: a prospective, multicenter, randomized, controlled study in China","volume":"9","author":"Lyu","year":"2020","journal-title":"Cancer Med"},{"key":"10.1016\/j.eclinm.2025.103689_bib28","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1002\/cac2.12601","article-title":"Concurrent chemoradiotherapy of different radiation doses and different irradiation fields for locally advanced thoracic esophageal squamous cell carcinoma: a randomized, multicenter, phase III clinical trial","volume":"44","author":"Zhang","year":"2024","journal-title":"Cancer Commun"},{"key":"10.1016\/j.eclinm.2025.103689_bib29","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1111\/1759-7714.15424","article-title":"The significance of consolidation chemotherapy after concurrent chemoradiotherapy in esophageal squamous cell carcinoma: a randomized controlled phase III clinical trial","volume":"15","author":"Zhu","year":"2024","journal-title":"Thorax Cancer"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537025006236?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537025006236?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T11:25:25Z","timestamp":1777634725000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537025006236"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":28,"alternative-id":["S2589537025006236"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2025.103689","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nivolumab with definitive chemoradiotherapy for oesophageal squamous cell carcinoma (NOBEL): a multicentre, single-arm, phase 2 feasibility trial","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2025.103689","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103689"}}